PEN-FAST Penicillin Allergy decision tool
Jump to navigation
Jump to search
Procedure
- points assigned
- allergy event occurred <= 5 years ago (2 points)
- anaphylaxis/angioedema or aevere cutaneous adverse reaction (2 points)
- treatment required for allergy episode (1 point)
Interpretation
- < 3 points = low risk (< 4% risk of significant reaction)[2]
More general terms
Additional terms
- penicillin
- type B drug reaction; drug-induced hypersensitivity syndrome; drug rash with eosinophilia & systemic symptoms (DIHS, DRESS)
References
- ↑ Trubiano JA, Vogrin S, Chua KYL et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med 2020 Mar 16; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32176248 PMCID: PMC7076536 Free PMC article https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2762878
- ↑ 2.0 2.1 Su C et al. Evaluating the PEN-FAST clinical decision-making tool to enhance penicillin allergy delabeling. JAMA Intern Med 2023 Jun 20; PMID: https://www.ncbi.nlm.nih.gov/pubmed/37338869 PMCID: PMC10282954 (available on 2024-06-20) https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2806194